The European Parliament's Public Health Committee adopted, with 33 votes, a report calling on the European Commission to draw up an action plan for rare diseases.
The 13th European Conference on Rare Diseases and Orphan Products (ECRD), held in Prague on June 3–4, 2026, came together in calling for a coordinated EU-wide action plan.
Prof. Dr. Hacer Durmuş Tekçe of the Turkish Neurological Society said that at least 5 million people in Türkiye are affected by rare diseases and that diagnosis can be delayed by 5–8 years.
Writing in NEJM, FDA leaders described an approval pathway called the 'plausible mechanism' pathway for individualized therapies for which randomized trials cannot be conducted.
The US Food and Drug Administration (FDA) announced 'Rare Disease Evidence Principles' for genetic diseases that generally have fewer than 1,000 patients in the USA.